About the study
AERIFY-1 was a Phase 3 study of itepekimab, an investigational antibody that blocks interleukin-33 (IL-33), compared with placebo in former smokers with moderate-to-severe COPD. The main goal was to see whether it reduced moderate or severe COPD flare-ups. Lung function and respiratory symptoms were also measured.
Who took part
The study enrolled people who:
- Were 40 to 85 years old
- Had moderate-to-severe COPD and were former smokers
Status at Veritas
This study has been completed. It is no longer enrolling, and it is listed here as part of Veritas Clinical Research's track record as a research site.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT04701983).